Triaziquone

Triaziquone

SCHEMBL2095563

C=C(C)C(=O)O.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
STAT3 P40763 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DNMT1 P26358 1/20 0.37
NSD2 O96028 2/20 0.31
APAF1 O14727 1/20 0.31
TDP2 O95551 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
TTR P02766 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL16419 0.90 MAPT (0.42) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL11422311 0.90 MAPT (0.42) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL10414999 0.88 MAPT (0.41) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL11744970 0.87 MAPT (0.40) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL9726159 0.86 TP53 (0.37) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL1241564 0.84 TP53 (0.36) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL7783197 0.84 MAPT (0.46) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL8507558 0.83 DNMT1 (0.41) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL2063810 0.83 MAPT (0.44) TP53MAPTSTAT3HTTSMN1; SMN2
Triaziquone SCHEMBL8585531 0.83 HTT (0.37) TP53MAPTSTAT3HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240184137-A1 CONTACT LENSES AND METHODS OF MAKING CONTACT LENSES UNIV FLORIDA (US) 2024-06-06 US claimed
WO-2022221259-A1 CONTACT LENSES AND METHODS OF MAKING CONTACT LENSES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2022-10-20 WO claimed
US-20200156336-A1 METHODS AND COMPOSITIONS FOR PIGMENTED HYDROGELS AND CONTACT LENSES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2020-05-21 US claimed
EP-1044227-A1 PARTIALLY POLYMERIZED MIXTURE OF DIETHYLENE GLYCOL (ALLYL CARBONATE) COMPOUNDS PPG Industries Ohio, Inc. (US) 2000-10-18 EP claimed
WO-1999033887-A1 PARTIALLY POLYMERIZED MIXTURE OF DIETHYLENE GLYCOL (ALLYL CARBONATE) COMPOUNDS PPG INDUSTRIES OHIO, INC. (US) 1999-07-08 WO claimed
US-20240184137-A1 CONTACT LENSES AND METHODS OF MAKING CONTACT LENSES UNIV FLORIDA (US) 2024-06-06 US disclosed
EP-4360861-A2 PROCESS OF MAKING AN OPHTALMICAL DEVICE FOR THE SUPPLY OF HYDROPHOBIC COMFORT AGENTS Alcon Inc. (CH) 2024-05-01 EP disclosed
EP-3373047-B1 PROCESS OF MAKING AN OPHTALMICAL DEVICE FOR THE SUPPLY OF HYDROPHOBIC COMFORT AGENTS ALCON INC (CH) 2024-03-06 EP disclosed
US-11905351-B2 Silicone hydrogel materials Envision Biomedical LLC (US) 2024-02-20 US disclosed
US-20240026049-A1 DUAL-PHASE ZWITTERIONIC MONOMERS Envision Biomedical LLC (US) 2024-01-25 US disclosed
US-11826974-B2 Methods and compositions for pigmented hydrogels and contact lenses UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-28 US disclosed
WO-2022221259-A1 CONTACT LENSES AND METHODS OF MAKING CONTACT LENSES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2022-10-20 WO disclosed
EP-0683799-A1 FLUOROSILICONE HYDROGELS BAUSCH & LOMB INCORPORATED (US) 1995-11-29 EP disclosed
US-5387662-A For contact lenses; acrylated polysiloxanes BAUSCH & LOMB INCORPORATED (US) 1995-02-07 US disclosed
WO-1994018253-A1 FLUOROSILICONE HYDROGELS BAUSCH & LOMB INCORPORATED (US) 1994-08-18 WO disclosed
US-5321108-A Improving solubility of unsaturated siloxane monomers in hydrophilic monomer BAUSCH & LOMB INCORPORATED (US) 1994-06-14 US disclosed
CN-1085844-A Making contains the method for the hydrogel lens of silicone BAUSCH & LOMB (US) 1994-04-27 CN disclosed
WO-1989001461-A1 CO-SINTERABLE METAL-CERAMIC PACKAGES AND MATERIALS THEREFOR CERAMICS PROCESS SYSTEMS CORPORATION (US) 1989-02-23 WO disclosed
US-4310615-A PRESSENSITIZED SHEET MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1982-01-12 US disclosed
US-4262079-A THIN, FLEXIBLE, TRANSPARENT SUBSTRATE, RELEASE COATING, PHOTOPOLYMERIZABLE OVERLAYER MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240026049-A1 DUAL-PHASE ZWITTERIONIC MONOMERS RAD1, RAD51, VCL TP53 2992/4885MAPT 2034/4885STAT3 4594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.